JP2015507478A5 - - Google Patents

Info

Publication number

JP2015507478A5

JP2015507478A5 JP2014551296A JP2014551296A JP2015507478A5 JP 2015507478 A5 JP2015507478 A5 JP 2015507478A5 JP 2014551296 A JP2014551296 A JP 2014551296A JP 2014551296 A JP2014551296 A JP 2014551296A JP 2015507478 A5 JP2015507478 A5 JP 2015507478A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

eye

composition according

injury

compound

Prior art date

2013-01-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 17
• 208000030533 eye disease Diseases 0.000 claims 9
• 150000001875 compounds Chemical class 0.000 claims 7
• 238000002347 injection Methods 0.000 claims 5
• 239000007924 injection Substances 0.000 claims 5
• 239000002773 nucleotide Substances 0.000 claims 5
• 125000003729 nucleotide group Chemical group 0.000 claims 5
• 125000002652 ribonucleotide group Chemical group 0.000 claims 5
• 208000020564 Eye injury Diseases 0.000 claims 4
• 208000010412 Glaucoma Diseases 0.000 claims 4
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 4
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 4
• 201000002761 non-arteritic anterior ischemic optic neuropathy Diseases 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
• 108091081021 Sense strand Proteins 0.000 claims 2
• 230000000692 anti-sense effect Effects 0.000 claims 2
• 239000007788 liquid Substances 0.000 claims 2
• 208000036460 primary closed-angle glaucoma Diseases 0.000 claims 2
• 150000003839 salts Chemical class 0.000 claims 2
• 208000024891 symptom Diseases 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• CKTSBUTUHBMZGZ-CHKWXVPMSA-N 4-amino-1-[(2s,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical group O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 CKTSBUTUHBMZGZ-CHKWXVPMSA-N 0.000 claims 1
• KKZFLSZAWCYPOC-VPENINKCSA-N Deoxyribose 5-phosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KKZFLSZAWCYPOC-VPENINKCSA-N 0.000 claims 1
• 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 1
• 208000030768 Optic nerve injury Diseases 0.000 claims 1
• 206010057430 Retinal injury Diseases 0.000 claims 1
• 208000027418 Wounds and injury Diseases 0.000 claims 1
• 201000001326 acute closed-angle glaucoma Diseases 0.000 claims 1
• 238000010276 construction Methods 0.000 claims 1
• 230000006378 damage Effects 0.000 claims 1
• 230000007812 deficiency Effects 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 230000004406 elevated intraocular pressure Effects 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 230000000302 ischemic effect Effects 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 201000006366 primary open angle glaucoma Diseases 0.000 claims 1
• 159000000000 sodium salts Chemical group 0.000 claims 1
• 230000000007 visual effect Effects 0.000 claims 1